Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2014

View Archived Issues

Cellerant's development of CLT-008 supported by additional government funding

Mimetas awarded funding for kidney-on-a-chip nephrotoxicity model

Evotec and the Jain Foundation expand dysferlin deficiency collaboration

First preclinical and clinical data presented for TLR7 agonist GSK-2245035

GlaxoSmithKline presents results for the antibacterial DNA topoisomerase 2 inhibitor

New class of compounds protects against blast-mediated TBI

Janssen Pharmaceutica provides grant to Harvard Medical School to combat DR-tuberculosis

NantBioScience and University of Colorado to develop novel anticancer drugs

Huya Bioscience establishes global joint venture with TIPR

Full results presented for SPARK study of sapropterin in infants with phenylketonuria

Janssen describes novel agents targeting elongation factor 2 for cancer

Results for the follow-up portion of phase II study evaluating blosozumab

RADIANCE results demonstrate RPC-1063 is a promising candidate for relapsing MS

CellProThera and BioCardia agree to partner on phase II EXCELLENT trial

Lysophospholipid S1P1 receptor modulators disclosed in Allergan patent

Janssen reports discovery of TLR7/TLR8 agonists

Merck KGaA patents cathepsin D inhibitors

GSK exercises option to novel muscle disease target discovered by Five Prime

Amarantus BioScience completes enrollment in Alzheimer's disease blood test trial

NicOx obtains antiviral eye drop program from Marinomed

DCVax-L is the first drug to be designated by U.K. authorities as a PIM

Eylea receives FDA breakthrough therapy designation for diabetic retinopathy

Oxygen Biotherapeutics will change name to Tenax Therapeutics

FDA approves naloxegol for opioid-induced constipation in patients with chronic pain

Denovo Biopharma licenses enzastaurin for development as a personalized therapy for DLBCL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...